Department of Synthesis and Chemical Technology of Pharmaceutical Substances with Computer Modeling Laboratory, Faculty of Pharmacy, Medical University of Lublin, 4 A Chodźki St., 20093, Lublin, Poland.
Department of Biopharmacy, Faculty of Pharmacy, Medical University of Lublin, 4 A Chodźki St., 20093, Lublin, Poland.
ChemMedChem. 2022 Aug 3;17(15):e202200238. doi: 10.1002/cmdc.202200238. Epub 2022 Jun 17.
Schizophrenia is a complex disease which is best treated with multitarget drugs, such as atypical antipsychotics. Previously, using structure-based virtual screening, we found a virtual hit, D2AAK1, with nanomolar affinity for dopamine and serotonin receptors important in schizophrenia pharmacotherapy. As a part of an optimization campaign of D2AAK1, we obtained 17 derivatives that also display a multitarget profile. Selected compounds were tested against off-targets in schizophrenia, i. e., histamine H receptor and muscarinic M receptor, and these did not display considerable affinity for these receptors. The two most promising compounds were subjected to behavioral studies. These compounds decreased amphetamine-induced hyperactivity in mice which indicates their antipsychotic potential. The compounds did not interfere with the memory consolidation in mice, as determined in the passive avoidance test. The favorable pharmacological profile of these compounds was rationalized using molecular modeling.
精神分裂症是一种复杂的疾病,最好采用多靶标药物治疗,如非典型抗精神病药。此前,我们通过基于结构的虚拟筛选发现了一个虚拟命中物 D2AAK1,它对多巴胺和 5-羟色胺受体具有纳摩尔亲和力,这些受体在精神分裂症的药物治疗中很重要。作为 D2AAK1 优化活动的一部分,我们获得了 17 种具有多靶标特征的衍生物。选择的化合物针对精神分裂症的非靶标进行了测试,即组胺 H 受体和毒蕈碱 M 受体,这些受体对这些受体没有表现出相当大的亲和力。两种最有前途的化合物进行了行为研究。这些化合物可减少小鼠中安非他命引起的过度活跃,表明它们具有抗精神病作用。在被动回避试验中,这些化合物不会干扰小鼠的记忆巩固。使用分子建模对这些化合物的有利药理特性进行了合理化。